HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Goro Matsumiya Norihide Fukushima Hajime Ichikawa Yoshiki Sawa Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Higuchi, T. Articles by Sawa, Y. Search for Related Content PubMed Articles by Higuchi, T. Articles by Sawa, Y. Related Collections Transplantation - heart

---

Original Articles: Adult Cardiac

Granulocyte Colony-Stimulating Factor Prevents Reperfusion Injury After Heart Preservation

^a Division of Cardiovascular Surgery, Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
^b Division of Cardiovascular Surgery, Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan

Accepted for publication December 18, 2007.

^_* Address correspondence to Dr Sawa, Division of Cardiovascular Surgery, Department of Surgery, Osaka University Graduate School of Medicine, Suita Osaka 565-0871, Japan (Email: sawa{at}surg1.med.osaka-u.ac.jp).

Background: Heart transplantation is an accepted method of treatment for selected patients with end-stage heart disease. Making prolonged heart preservation safer will benefit patients awaiting heart transplantation. Granulocyte colony-stimulating factor (G-CSF) exhibited protective effects against myocardial ischemia–reperfusion injury mediated through the Janus kinase (Jak)/(signal transducer and activator of transcription (Stat) pathway. We examined whether pharmacologic preconditioning with G-CSF improves cardiac function after heart preservation.

Methods: Male rats were divided into four groups: group A, saline injection; group B, G-CSF, 10 µg/kg; group C, G-CSF, 100 µg/kg; and group D, G-CSF, 100 µg/kg plus AG490 (a selective Jak2 inhibitor), 1 mg/kg. The G-CSF and AG490 were given intravenously for 3 consecutive days. Four hours after the final treatment, isolated rat hearts underwent 12 hours of hypothermic (4°C) preservation, followed by 60 minutes of normothermic reperfusion.

Results: Stat3 phosphorylation was observed in the heart at 15 minutes after G-CSF treatment in group C, but this was attenuated by additional treatment with AG 490 in group D. Compared with group A, group C exhibited significant recovery of left ventricular pressure, maximum positive rate of left ventricular developed pressure (Max dP/dt), and coronary flow (p < 0.05, respectively), as well as lower creatine phosphokinase leakage during reperfusion (p < 0.05). Group B and group D did not show significant hemodynamic recovery during reperfusion. In group C, increased Bcl-xL and decreased Bax expressions as well as decreased terminal deoxynucleotide transferase-mediated deoxy uridine triphosphate nick-end labeling (TUNEL)-positive cardiomyocytes were observed after reperfusion. Immunohistochemical examination showed significantly increased capillary density before hypothermic preservation in group C, but not in other groups.

Conclusions: Pharmacologic preconditioning with G-CSF protected hearts from prolonged hypothermic ischemia–reperfusion injury.